The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening
Open accessAbstract
IMPORTANCE: The US Preventive Services Task Force (USPSTF) recommends computed tomography (CT) lung cancer screening for ever-smokers aged 55 to 80 years who have smoked at least 30 pack-years with no more than 15 years since quitting. However, selecting ever-smokers for screening using individualized lung cancer risk calculations may be more effective and efficient than current USPSTF recommendations. OBJECTIVE: Comparison of modeled outcomes from risk-based CT lung-screening strategies vs USPSTF recommendations. DESIGN, SETTING, AND PARTICIPANTS: Empirical risk models for lung cancer incidence and death in the absence of CT screening using data on ever-smokers from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO; 1993-2009) control group. Covariates included age; education; sex; race; smoking intensity, duration, and quit-years; body mass index; family history of lung cancer; and self-reported emphysema. Model validation in the chest radiography groups of the PLCO and the National Lung Screening Trial (NLST; 2002-2009), with additional validation of the death model in the National Health Interview Survey (NHIS; 1997-2001), a representative sample of the United States. Models were applied to US ever-smokers aged 50 to 80 years (NHIS 2010-2012) to estimate outcomes of risk-based selection for CT lung screening, assuming screening for all ever-smokers, yield the percent changes in lung cancer detection and death observed in the NLST. EXPOSURES: Annual CT lung screening for 3 years beginning at age 50 years. MAIN OUTCOMES AND MEASURES: For model validity: calibration (number of model-predicted cases divided by number of observed cases [estimated/observed]) and discrimination (area under curve [AUC]). For modeled screening outcomes: estimated number of screen-avertable lung cancer deaths and estimated screening effectiveness (number needed to screen [NNS] to prevent 1 lung cancer death). RESULTS: Lung cancer incidence and death risk models were well calibrated in PLCO and NLST. The lung cancer death model calibrated and discriminated well for US ever-smokers aged 50 to 80 years (NHIS 1997-2001: estimated/observed = 0.94 [95%CI, 0.84-1.05]; AUC, 0.78 [95%CI, 0.76-0.80]). Under USPSTF recommendations, the models estimated 9.0 million US ever-smokers would qualify for lung cancer screening and 46,488 (95% CI, 43,924-49,053) lung cancer deaths were estimated as screen-avertable over 5 years (estimated NNS, 194 [95% CI, 187-201]). In contrast, risk-based selection screening of the same number of ever-smokers (9.0 million) at highest 5-year lung cancer risk (≥1.9%) was estimated to avert 20% more deaths (55,717 [95% CI, 53,033-58,400]) and was estimated to reduce the estimated NNS by 17% (NNS, 162 [95% CI, 157-166]). CONCLUSIONS AND RELEVANCE: Among a cohort of US ever-smokers aged 50 to 80 years, application of a risk-based model for CT screening for lung cancer compared with a model based on USPSTF recommendations was estimated to be associated with a greater number of lung cancer deaths prevented over 5 years, along with a lower NNS to prevent 1 lung cancer death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2771 · Cited by 2,632
Analysis of Complex Survey Samples
Lumley, T. (2004) · Journal of Statistical Software · doi:10.18637/jss.v009.i08 · Cited by 2,425
Edwards, B. K., Noone, A., Mariotto, A. B., Simard, E. P., Boscoe, F. P., Henley, S. J., Jemal, A., Cho, H., Anderson, R. N., Kohler, B. A., et al. (2014) · Cancer · doi:10.1002/cncr.28509 · Cited by 1,210
Selection Criteria for Lung-Cancer Screening
Tammemägi, M. C., Katki, H. A., Hocking, W. G., Church, T. R., Caporaso, N., Kvale, P. A., Chaturvedi, A. K., Silvestri, G. A., Riley, T. L., Commins, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211776 · Cited by 1,029
Self-citationMassad, L. S., Einstein, M. H., Huh, W. K., Katki, H. A., Kinney, W. K., Schiffman, M., Solomon, D., Wentzensen, N., & Lawson, H. W. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3182883a34 · Cited by 922
Self-citationOken, M. M., Hocking, W. G., Kvale, P. A., Andriole, G. L., Buys, S. S., Church, T. R., Crawford, E. D., Fouad, M. N., Isaacs, C., Reding, D. J., et al. (2011) · JAMA · doi:10.1001/jama.2011.1591 · Cited by 655
Self-citationVariations in Lung Cancer Risk Among Smokers
Bach, P. B., Kattan, M. W., Thornquist, M. D., Kris, M. G., Tate, R. C., Barnett, M. J., Hsieh, L. J., & Begg, C. B. (2003) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.470 · Cited by 642
Targeting of Low-Dose CT Screening According to the Risk of Lung-Cancer Death
Kovalchik, S. A., Tammemagi, M., Berg, C. D., Caporaso, N. E., Riley, T. L., Korch, M., Silvestri, G. A., Chaturvedi, A. K., & Katki, H. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301851 · Cited by 575
Self-citationCost-Effectiveness of CT Screening in the National Lung Screening Trial
Black, W. C., Gareen, I. F., Soneji, S. S., Sicks, J. D., Keeler, E. B., Aberle, D. R., Naeim, A., Church, T. R., Silvestri, G. A., Gorelick, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312547 · Cited by 544
Cited by
Bade, B. C., & Dela Cruz, C. S. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.001 · Cited by 1,911
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology
Wood, D. E., Kazerooni, E. A., Baum, S. L., Eapen, G. A., Ettinger, D. S., Hou, L., Jackman, D. M., Klippenstein, D., Kumar, R., Lackner, R. P., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0020 · Cited by 611
European position statement on lung cancer screening
Oudkerk, M., Devaraj, A., Vliegenthart, R., Henzler, T., Prosch, H., Heussel, C. P., Bastarrika, G., Sverzellati, N., Mascalchi, M., Delorme, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30861-6 · Cited by 587
Lung cancer LDCT screening and mortality reduction — evidence, pitfalls and future perspectives
Oudkerk, M., Liu, S., Heuvelmans, M. A., Walter, J. E., & Field, J. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00432-6 · Cited by 519
Metadata
- Authors
- Katki, H. A., Kovalchik, S. A., Berg, C. D., Cheung, L. C., & Chaturvedi, A. K.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-06-07
- Volume
- 315
- Issue
- 21
- Pages
- 2300
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2367428707
- Cited by
- 338
- References
- 30
- FWCI
- 25.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. https://app.cochat.ai/papers/10.1001/jama.2016.6255
- The paper
- Katki, H. A., Kovalchik, S. A., Berg, C. D., Cheung, L. C., & Chaturvedi, A. K. (2016). Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. JAMA. https://doi.org/10.1001/jama.2016.6255
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.